Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs

Cardiovascular Research

Volumn 31, Issue 2, 1996, Pages 296-305

  Bagrov, Alexei Y ^a,b   Fedorova, Olga V ^a,b   Dmitrieva, Renata I ^b   French, Alan W ^a   Anderson, David E ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

Bufodienolide; Dog, anesthetized; Endogenous digitalis like factor (EDLF); Marinobufagenin; Na+ K+ ATPase inhibitors; Ouabain; Plasma volume expansion

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; DIGOXIN ANTIBODY; OUABAIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; HYPERVOLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AUTOANTIBODIES; BUFANOLIDES; BUFO MARINUS; CARDENOLIDES; DIGOXIN; DOGS; FLUID SHIFTS; IMMUNE SERA; MALE; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; PLASMA VOLUME; SAPONINS; SODIUM CHLORIDE;

EID: 0029926917     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(95)00208-1     Document Type: Article

References (57)

1. Goto A, Yamada K, Yagu N, Yoshioka M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992;44:377-399.
2. Hamlyn JM, Manunta P. Ouabain, digitalis-like factors and hypertension. J Hypertens 1992;10(Suppl 7):S99-S111.
3. Pamnani M, Huot S, Buggy J, Clough D, Haddy F. Demonstration of a humoral inhibitor of the Na,K pump in some models of experimental hypertension. Hypertension 1981;3(Suppl 2):96-101.
4. Hamlyn JM, Ringel M, Schaeffer JS, Levinsin PD, Hamilton BP, Kowarski AV, Blaustein MP. A circulating inhibitor of the Na,K-ATPase associated with essential hypertension. Nature 1982;300:650-652.
5. De The H, Devynck MA, Rosenfeld J, Pernollet M-G, Elghozi J-L, Meyer P. Plasma sodium oumo inhibitor in essential hypertension and normotensive subjects with hypertensive heredity. J Cardiovasc Pharmacol 1984;6(Suppl I):S49-S53.
6. Haddy FJ, Overbeck HW. The role of humoral agents in volume-dependent hypertension. Life Sci 1976;30:935-948.
7. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol 1977;232:C167-C173.
8. Hamlyn JM. Increased levels of a humoral digitalis-like factor in deoxycorticosterone acetate-induced hypertension in the pig. J Endocrinol 1989;122:409-420.
9. Wauquier I, Pernollet M-G, Grichois ML, Jacour B, Meyer P, Devynck M-A. Endogenous digitalis-like circulating substances in spontaneously hypertensive rats. Hypertension 1988;12:108-116.
10. Pamnani MB, Clough DL, Huot SJ, Haddy FJ. Sodium-potassium pump activity in experimental hypertension. In: Vanhoutte PM, Leusen I (Eds), Vasodilation. Raven Press, New York 1981;391-403.
11. Kojima I, Yoshihara S, Ogata E. Involvement of endogenous digitalis-like substance in genesis of deoxycorticosterone-salt hypertension. Life Sci 1982;30:1775-1781.
12. Kunes J, Stolba P, Pohlova I, Jelinek J, Zicha J. The importance of endogenous digoxin-like factors in rats with various forms of experimental hypertension. Clin Exp Hypertens 1985;7:707-720.
13. Ludens JH, Clark MA, DuCharme DW, Harris DW, Lutzke BS, Mandel F, Mathews WR, Sutler DM, Hamlyn JM. Purification of an endogenous digitalis-like factor from human plasma for structural analysis. Hypertension 1991;17:923-929.
14. Kelly RA, O'Hara DS, Canessa ML, Mitch WE, Smith TW. Characterization of digitalis-like factors in human plasma. Interactions with NaK-ATPase and cross-reactivity with cardiac glycoside-specific antibodies. J Biol Chem 1985;260:11396-11405.
15. Shaikh IM, Lau BWC, Siegfried BA, Valdes R Jr. Isolation of digoxin-like immunoreactive material from mammalian adrenal cortex. J Biol Chem 1991;266:13672-13678.
16. Flier JC. Ouabain-like activity in toad skin and its implications for endogenous regulation of ion transport. Nature 1978;274:285-287.
17. Chen KK, Kowarikowa A. Pharmacology and toxicology of toad venom. J Pharmacol Sci 1967;56:1535-1542.
18. Cress LW, Freas W, Haddy F, Muldoon S. Effect of bufalin on norepinephrine turnover in canine saphenous vein. Hypertension 1991;10:516-522.
19. Oberfrank F, Vizi ES, Baker PF, Samuelov S, Lichtstein D. Comparison of the effects of a bufodienolide and ouabain on neuronal and smooth muscle preparations. Neurosci Res 1991;10:235-244.
20. Bagrov AY, Roukoyatkina NI, Fedorova OV, Pinaev AG, Ukhanova MV. Digitalis-like and vasoconstrictor properties of endogenous digoxin-like factor(s) from the venom of Bufo marinus toad. Eur J Pharmacol 1993;234:165-172.
21. Bagrov AY, Roukoyatkina NI, Pinaev AG, Dmitrieva RI, Fedorova OV. Effects of two Na,K-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol 1995;274:151-158.
22. Kieval RS, Butler VP, Derguini F, Bruening RC, Rosen MR. Cellular electrophysiologic effects of vertebrate digitalis-like substances. J Am Coll Cardiol 1988;11:637-643.
23. Naomi S, Graves S, Lazarus M, Williams GH, Hollenberg NK. Variation in apparent serum digitalis-like factor levels with different digoxin antibodies. The "immunological fingerprint". Am J Hypertens 1991;4:795-801.
24. Lichtstein D, Gati I, Samuelov S, Berson D, Rozenman Y, Landau L, Deutsch J. Identification of digitalis-like compounds in human cataractous lenses. Eur J Biochem 1988;216:261-268.
25. Schoner W, Kirch U, Sich B, Antolovich R. Purification and some properties of an inhibitor of the sodium pump from bovine adrenals cross-reacting with proscillaridin A antibodies. (Abstract) Biol Chem Hoppe-Seyler 1993;374:SP-181.
26. Bagrov A, Dmitrieva R, Roukoyatkina N, Kuznetsova E. Nature and importance of endogenous digitalis-like factors in acute myocardial ischemia. (Abstract) J Mol Cell Cardiol 1994;26:P393.
27. Buckalew VM Jr, Nelson DB. Natriuretic and sodium transport inhibitory activity in plasma of volume expanded dogs. Kidney Int 1974;5:12-22.
28. Graves SW, Sharma K, Chandler A. Methods for eliminating interferences in digoxin immunoassays caused by digoxin-like factors. Clin Chem 1986;32:1506-1509.
29. Barbier M, Shroter H, Meyer K, Schindler O, Reichstein T. Die Bufogenine des Paratoidensekrets von Bufo marinus (L) Schneider. Helv Chim Acta 1959;42:2486-2506.
30. Zelnik R, Ziti LM. Thin-layer chromatography. Chromatoplate analysis of the bufodienolides isolated from toad venom. J Chromatogr 1962;9:37-39.
31. Koenigs E, Knorr E. Uber einige Derivate des Traubenzuskers und der Galactose. Ber Deut Chem Ges 1901;34:161-169.
32. Wulf G, Kruger W. Die Umsetzung in a-Acetobromglukose mit den Silbersalzen Hydroxycarbonsauren. Chem Ber 1971;104:1387-1398.
33. Curd J, Smith TW, Jaton J-C, Haber E. The isolation of digoxin specific antibody and its use in the reversal of the effects of digoxin. Proc Natl Acad Sci USA 1971;68:2401-2406.
34. McKinney MM, Parkinson A. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Meth 1987;96:271-278.
35. Helsingius P, Hemmila I, Lovgren T. Solid phase immunoassay of digoxin by measuring time resolved fluorescence. Clin Chem 1986;32:1767-1769.
36. Nutbourne DM, Howse JD, Schrier RW, Talner LB, Ventom MG, Verroust PJ, de Wardener HE. The effect of the blood volume of a dog on the short-circuit current across an isolated frog skin incorporated in the dog's circulation. Clin Sci 1970;38:629-648.
37. Keck W, Joppich R, v. Restorff WD, Finsterer U, Prucksunand P, Brechtelsbauer H, Kramer K. Sodium excretion in conscious and anesthetised dogs after large saline infusions. Pflugers Arch 1973;341:51-62.
38. Romagnoli A. A comparative study of blood pressure measurements in dogs. Cornell Vet 1953;43:161-175.
39. Eliades D, Swindall B, Johnston J, Pamnani M, Haddy F. Hemodynamic effects of bufalin in anesthetized dog. Hypertension 1989;13:690-695.
40. Conway J. Hemodynamic consequences of induced changes in blood volume. Circ Res 1966;18:190-198.
41. Roukoyatkina N, Dmitrieva R, Fedorova O, Anderson D, Bagrov A. Differential vasoactive effects of endogenous digitalis-like factors (EDLF). Biol Chem Hoppe-Seyler 1993;374:SP-180.
42. Bagrov AY, Anderson DE, Dmitrieva RI, Fedorova OV, French AW. Endogenous bufodienolide Na,K-ATPase inhibitor in plasma volume expansion. (Abstract) Hypertension 1994;24:407.
43. Toma S, Hirai Y, Sugimoto C, Shoji M, Oguni Y, Morishita S, Ito C, Horie M. Metabolic fate of bufalin and cinobufagin. Yakugaku Zasshi -J Pharmaceut Soc Japan 1991;111:687-694.
44. Zhang L, Aoki K, Yoshida T, Kuroiwa Y. Deacetylation of cinobufagin by rat liver. Drug Metab Dispos 1992;20:52-55.
45. Urtizberea M, Sabouraud A, Lachaise M, Chappey O, Cosson V, Baud FJ, Scherrmann JM. Pharmacokinetics of total and free digoxin and Fab fragments in 5 intoxicated patients after administration of specific anti-digoxin Fab fragments. Arch Toxicol 1991;14(Suppl): 132-135.
46. Scherrmann JM. Antibody treatment of toxin poisoning - recent advances. J Toxicol - Clin Toxicol 1994;32:363-375.
47. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992;86:420-425.
48. Doris P, Jenkins L, Stocco M. Is ouabain an authentic endogenous mammalian substance derived from the adrenal? Hypertension 1994;23:632-638.
49. Lewis LK, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ, Nicholls MG. Ouabain is not detectible in human plasma. Hypertension 1994;24:549-555.
50. Tymiak AA, Norman JA, Bolgar M, DiDonato GC, Lee H, Parker WL, Lo L-C, Berova N, Nakanishi K, Haber E, Haupert GT Jr. Physicochemical characterization of an ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993;90:8189-8193.
51. Schon R, Weiland J, Megges R, Repke KRH. Towards understanding the molecular mechanism of the inhibitory cardiac glycoside interaction with the receptor enzyme Na/K-transporting ATPase. In: Bamberg E, Schoner W. (Eds), The Sodium Pump. Structure, Mechanism, Hormonal Control and its Role in Disease. Steinkopff Verlag GmbH, Darmstadt, 1994;381-384.
52. Juhaszova M, Mercer RW, Weiss DN, Podbersky DJ, Heidrich J, Blaustein MP. Na/K-pump alpha-3 isoform in rat vascular smooth muscle and its physiological role. In: Bamberg E, Schoner W. (Eds), The Sodium Pump. Structure, Mechanism, Hormonal Control and its Role in Disease. Steinkopff Verlag GmbH, Darmstadt, 1994;852-855.
53. Sahin-Erdemli I, Rashed SM, Songu-Mize E. Rat vascular tissues express all three isoforms of Na,K-ATPase. Am J Physiol 1994;266:H350-353.
54. Shull MM, Greeb J, Lindgrel JB. Molecular cloning of three distinct forms of Na,K-ATPase alpha subunit from rat brain. Biochemistry 1986;25:8125-8132.
55. Leenen FH, Harmsen E, Yu H. Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. Am J Physiol 1994;267:H1916-H1920.
56. Gruber KA, Whitaker JM, Buckalew VM Jr. Endogenous digitalis-like substance in plasma of volume expanded dogs. Nature 1980;287:743-745.
57. Morris RG, Frewin DB, Saccoia NC, Golsworthy WL, Jeffries WS, McPhee AJ. Interference from digoxin-like substance(s) in commercial digoxin kit methods. Eur J Clin Pharmacol 1990;39:359-363.